<DOC>
	<DOC>NCT03059797</DOC>
	<brief_summary>To compare the effects and safety of Anlotinib with placebo in patients with small cell lung cancer(SCLC).</brief_summary>
	<brief_title>Study of Anlotinib in Patients With Small Cell Lung Cancer (ALTER1202)</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<criteria>Histological documentation of small cell lung cancer Advanced small cell lung cancer who had at least two chemotherapy regimens,at least one measurable lesion (by RECIST1.1) 1875 years,ECOG PS:02,Life expectancy of more than 3 months Main organs function is normal Women of childbearing potential should agree to use and utilize an adequate method of contraception (such as intrauterine device，contraceptive and condom) throughout treatment and for at least 6 months after study is stopped；the result of serum or urine pregnancy test should be negative within 7 days prior to study enrollment，and the patients required to be nonlactating；Man participants should agree to use and utilize an adequate method of contraception throughout treatment and for at least 6 months after study is stopped Patients should participate in the study voluntarily and sign informed consent Patients who have been used anlotinib Patients who have been used targeted drugs(such as sunitinib,bevacizumab,endostar),Immune targeted drugs 4 weeks or less from the last cytotoxic therapy, radiation therapy or surgery Patients whose primary lesion with active bleeding within 4 months Carcinomatous meningitis Patients who known to the central nervous system Patients with factors that could affect oral medication (such as dysphagia，chronic diarrhea, intestinal obstruction etc.) Patients with any severe and/or unable to control diseases，including： 1. Blood pressure unable to be controlled ideally(systolic pressure≥150 mmHg，diastolic pressure≥100 mmHg); 2. Patients with Grade 1 or higher myocardial ischemia, myocardial infarction or malignant arrhythmias(including QTc≥450ms(male),QTc≥470ms（female）) and patients with Grade 1 or higher congestive heart failure (NYHA Classification); 3. Patients with active or unable to control serious infections; 4. Patients with cirrhosis, decompensated liver disease, or active hepatitis; 5. Patients with poorly controlled diabetes (fasting blood glucose(FBG)＞10mmol/L) 6. Urine protein ≥ ++，and 24hour urinary protein excretion＞1.0 g confirmed; Patients with nonhealing wounds or fractures Patients with arterial or venous thromboembolic events occurred within 6 months, such as cerebrovascular accident (including transient ischemic attack), deep vein thrombosis and pulmonary embolism Patients with drug abuse history and unable to get rid of or Patients with mental disorders Imaging showed tumors have involved important blood vessels or by investigators determine likely during the followup study and cause fatal hemorrhage History of immunodeficiency Patients with concomitant diseases which could seriously endanger their own safety or could affect completion of the study according to investigators' judgment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>